Adcock Ingram has posted a 6% rise in annual revenue, helped by strong demand for immune-boosting products, as well as some linked to the treatment of Covid-19.
The pharmaceutical manufacturer’s earnings, however, took a knock.
Alishia Seckam spoke to CEO Andy Hall for more detail.
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.